KRYS Krystal Biotech Inc

Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference

Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference

PITTSBURGH, March 02, 2023 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the 43rd Annual TD Cowen Health Care Conference, which is taking place in Boston from March 6-8.

Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the conference and host investor meetings on March 7 at 10:30am ET.

A webcast of the presentation will be available , and an archived version of the webcast will be available following the presentation on the Investor section of the Company’s .

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The Company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. Headquartered in Pittsburgh, Pennsylvania, the Company is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization. For more information, please visit , and follow @KrystalBiotech on and .

CONTACT:

Investors and Media                 

Meg Dodge

Krystal Biotech



EN
02/03/2023

Underlying

KRYSKrystal Biotech Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Krystal Biotech Inc

Free Trial
KRYS Krystal Biotech...

Krystal Biotech Inc: 1 director

A director at Krystal Biotech Inc sold 25,000 shares at 220.150USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

KRYS KRYSTAL BIOTECH INC
12/08/25 December 8, 2025 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech to Present at 8th Annual Evercore Healthcare Conferenc...

Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference PITTSBURGH, Nov. 26, 2025 (GLOBE NEWSWIRE) -- . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025, in Miami. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 10:00 am ET and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 10:00 am ET on Wednesday, December 3, 2025 and will be posted on the Investors section o...

November 26, 2025 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech Announces Third Quarter 2025 Financial and Operating R...

Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results $97.8 million in 3Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in 4Q Updated U.S. VYJUVEK label expands eligible patient population and provides greater patient flexibility FDA grants platform technology designation CF interim results expected in 4Q Strong balance sheet, ending the quarter with $864.2 million in cash and investments PITTSBURGH, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) to...

November 3, 2025 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech to Report Third Quarter 2025 Financial Results on Nove...

Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025 PITTSBURGH, Oct. 21, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, November 3, 2025, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: . For those unable to listen to the live webcast...

October 21, 2025 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech Receives FDA Platform Technology Designation for HSV-1...

Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform technology designation to the genetically modified, non-replicating herpes simplex virus type 1 (HSV-1) viral vector used in the Company’s redosable eye drop gene therapy KB801, currently under evaluation in a randomized placebo controlled trial for the treatment of neurotrophic kera...

October 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch